<DOC>
	<DOCNO>NCT01891864</DOCNO>
	<brief_summary>The purpose study demonstrate equivalent efficacy GP2015 Enbrel® patient moderate severe chronic plaque-type psoriasis respect PASI 75 response rate Week 12 .</brief_summary>
	<brief_title>Study Demonstrate Equivalent Efficacy Compare Safety Biosimilar Etanercept ( GP2015 ) Enbrel</brief_title>
	<detailed_description>The purpose confirmatory safety efficacy study ( GP15-302 ) demonstrate equivalence efficacy similarity safety immunogenicity GP2015 Enbrel ( EU-authorized ) patient moderate severe chronic plaque-type psoriasis evaluate effect repeat switch GP2015 Enbrel efficacy , overall safety , immunogenicity . Since EU-authorized Enbrel utilized study , use term `` Enbrel '' throughout report describe EU-authorized Enbrel .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Men woman least 18 year age time screen Chronic plaquetype psoriasis diagnose least 6 month baseline Moderate severe psoriasis define baseline : PASI score 10 great , Investigator´s Global Assessment score 3 great ( base scale 0 4 ) , Body Surface Area affect plaquetype psoriasis 10 % great Chronic plaquetype psoriasis patient previously receive phototherapy systemic psoriasis therapy least candidate therapy opinion investigator . Forms psoriasis chronic plaquetype Druginduced psoriasis Ongoing use prohibit treatment Previous exposure etanercept Active ongoing inflammatory disease psoriasis might confound evaluation benefit treatment etanercept Other In/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>